Literature DB >> 28815955

The role of IQSEC2 in syndromic intellectual disability: Narrowing the diagnostic odyssey.

Benjamin M Helm1, Zoe Powis2, Carlos E Prada3,4, Olga L Casasbuenas-Alarcon5, Tonya Balmakund6, G B Schaefer7, Stephen G Kahler7, Julie Kaylor8, Susan Winter9, Yuri A Zarate7, Samantha A Schrier Vergano10,11.   

Abstract

While X-linked intellectual disability (XLID) syndromes pose a diagnostic challenge for clinicians, an increasing number of recognized disorders and their genetic etiologies are providing answers for patients and their families. The availability of clinical exome sequencing is broadening the ability to identify mutations in genes previously unrecognized as causing XLID. In recent years, the IQSEC2 gene, located at Xp11.22, has emerged as the cause of multiple cases of both nonsyndromic and syndromic XLID. Herein we present a case series of six individuals (five males, one female) with intellectual disability and seizures found to have alterations in IQSEC2. In all cases, the diagnostic odyssey was extensive and expensive, often including invasive testing such as muscle biopsies, before ultimately reaching the diagnosis. We report these cases to demonstrate the exhaustive work-up prior to finding the changes in IQSEC2 gene, recommend that this gene be considered earlier in the diagnostic evaluation of individuals with global developmental delay, microcephaly, and severe, intractable epilepsy, and support the use of intellectual disability panels including IQSEC2 in the first-line evaluation of these patients.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  IQSEC2; X-linked intellectual disability; exome; microcephaly; seizures

Mesh:

Substances:

Year:  2017        PMID: 28815955     DOI: 10.1002/ajmg.a.38404

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  5 in total

1.  Bi-allelic Variants in IQSEC1 Cause Intellectual Disability, Developmental Delay, and Short Stature.

Authors:  Muhammad Ansar; Hyung-Lok Chung; Ali Al-Otaibi; Mohammad Nael Elagabani; Thomas A Ravenscroft; Sohail A Paracha; Ralf Scholz; Tayseer Abdel Magid; Muhammad T Sarwar; Sayyed Fahim Shah; Azhar Ali Qaisar; Periklis Makrythanasis; Paul C Marcogliese; Erik-Jan Kamsteeg; Emilie Falconnet; Emmanuelle Ranza; Federico A Santoni; Hesham Aldhalaan; Ali Al-Asmari; Eissa Ali Faqeih; Jawad Ahmed; Hans-Christian Kornau; Hugo J Bellen; Stylianos E Antonarakis
Journal:  Am J Hum Genet       Date:  2019-10-10       Impact factor: 11.025

2.  Heterozygous loss of function of IQSEC2/Iqsec2 leads to increased activated Arf6 and severe neurocognitive seizure phenotype in females.

Authors:  Matilda R Jackson; Karagh E Loring; Claire C Homan; Monica Hn Thai; Laura Määttänen; Maria Arvio; Irma Jarvela; Marie Shaw; Alison Gardner; Jozef Gecz; Cheryl Shoubridge
Journal:  Life Sci Alliance       Date:  2019-08-22

3.  Xp11.2 Duplication in Females: Unique Features of a Rare Copy Number Variation.

Authors:  Márta Czakó; Ágnes Till; Judith Zima; Anna Zsigmond; András Szabó; Anita Maász; Béla Melegh; Kinga Hadzsiev
Journal:  Front Genet       Date:  2021-04-14       Impact factor: 4.599

4.  IQSEC2-related encephalopathy in males due to missense variants in the pleckstrin homology domain.

Authors:  Cheryl Shoubridge; Tracy Dudding-Byth; Laurent Pasquier; Himanshu Goel; Patrick Yap; Vivienne McConnell
Journal:  Clin Genet       Date:  2022-04-06       Impact factor: 4.296

5.  Differences in Expression of IQSEC2 Transcript Isoforms in Male and Female Cases with Loss of Function Variants and Neurodevelopmental Disorder.

Authors:  Beatriz Baladron; Lidia M Mielu; Estrella López-Martín; Maria J Barrero; Lidia Lopez; Jose I Alvarado; Sara Monzón; Sarai Varona; Isabel Cuesta; Rosario Cazorla; Julián Lara; Gemma Iglesias; Enriqueta Román; Purificación Ros; Gema Gomez-Mariano; Isabel Cubillo; Esther Hernandez-San Miguel; Daniel Rivera; Javier Alonso; Eva Bermejo-Sánchez; Manuel Posada; Beatriz Martínez-Delgado
Journal:  Int J Mol Sci       Date:  2022-08-22       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.